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Background: This study is aimed to evaluate the clinical significance of heart rate turbulence (HRT) parameters in
predicting the prognosis in patients with chronic heart failure (CHF).
Methods: From June 2011 to December 2012, a total of 104 CHF patients and 30 healthy controls were enrolled in
this study. We obtained a 24-hour Holter ECG recording to assess the HRT parameters, included turbulence onset
(TO), turbulence slope (TS), standard deviation of N-N intervals (SDNN), and resting heart rate (RHR). The relationships
between HRT parameters and the prognosis of CHF patients were determined.
Results: The assessment follow-up period lasted until January 31, 2013. The overall mortality of CHF patients was 9.6%
(10/104). Our results revealed that CHF patients had higher levels of TO than those of healthy subjects, but the TS
levels of CHF patients were lower than that of the control group. CHF patients with NYHA grade IV had higher
HRT1/2 rate than those with NYHA grade II/III. There were statistical differences in TS, LVEF, SDNN and RHR between the
non-deteriorating group and the non-survivor group. Significant differences in TS among the three groups were also
found. Furthermore, CHF patients in the non-survivor group had lower levels of TS than those in the deteriorating
group. Correlation analyses indicated that TO negatively correlate with SDNN, while TS positively correlated with SDNN
and left ventricular ejection fraction (LVEF). We also observed negative correlations between TS and left ventricular
end-diastolic cavity dimension (LVEDD), RHR, homocysteine (Hcy) and C-reactive protein (CRP). Multivariate Cox
regression analysis further confirmed that LVEF (≤30%), HRT2, SDNN and RHR were independent risk factors which
can indicate poor prognosis in CHF patients.
Conclusions: Our findings indicate that HRT may have good clinical predictive value in patients with CHF. Thus,
quantifying HRT parameters could be a useful tool for predicting mortality in CHF patients.
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Chronic heart failure (CHF), one of the most common
forms of heart failure, is a pathophysiological state in
which an abnormality of cardiac function is responsible
for the failure of the heart to pump blood at a rate ne-
cessary to deliver nutrients to metabolizing tissues [1].
Despite advances in medical and surgical treatments,
mortality in CHF patients remains high, and the five-year
mortality rate in CHF patients averages 50%, whereas in
the end-stage CHF, it may reach 75%; and the sudden
death rate accounts for 30 ~ 50% of total mortality [2,3].* Correspondence: hbmu1h_qxf@163.com
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unless otherwise stated.Recent studies have confirmed that the prognosis of CHF
is uniformly poor, and the accuracy of diagnosis through
clinical means alone is often inadequate, particularly in
elderly obese people [4,5]. Currently, several studies have
indicated that various indices or electrocardiographically
derived parameters have been commonly used and tested
as prognostic predictors for CHF [6,7].
Clinically, the currently accepted prognostic indicators
for CHF mainly consist of heart rate variability (HRV)
and LVEF, which may both have some limitations to
their own extents [8]. HRV, as one of the oldest Holter-
derived risk stratification parameters, is an established
parameter for analyzing the performance of autonomic
regulation in the sinus node [9]. Nevertheless, it is only
mildly inclined to a series of physiological reflexes caused. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cannot reflect the instantaneous malignant arrhythmias.
[10]. As for LVEF, it primarily reflects mechanical LV sys-
tolic function, however, in the clinical there were a large
number of patients suffering from a high risk of sudden
death who only detected a mild to moderate left ventricu-
lar function with CHF [11,12]. Therefore, it might be es-
sential to actively explore other useful and valid predictors
for CHF sufferers since the existing clinical techniques
may be inappropriate to applied as a biomarker of high
risk of sudden death in CHF.
Heart rate turbulence (HRT), modulated by the baro-
receptor reflex, is a physiological biphasic response of
the sinus node to premature ventricular contractions,
which involves a short initial acceleration followed by a
deceleration of the sinus rhythm due to the baroreflex.
[13] There are two numeric descriptors that are usually
employed to quantify HRT parameter: one is the turbu-
lence onset (TO), which reflects the initial acceleration
of heart rate after a ventricular premature beat (VPB);
the other is the turbulence slope (TS), which is used to
describe subsequent deceleration of heart rate following
a ventricular premature beat [13,14]. Previous studies
have shown that HRT assessment might be an important
parameter in risk stratification after MI and has been
suggested that it could be used as a measure of auto-
nomic dysfunction [15,16]. Clinically, HRT can facilitate
the predictive accuracy of nonsustained ventricular tachy-
cardia (NSVT) in identifying patients at risk for serious
arrhythmic events and in patients with left ventricular
(LV) dysfunction [17]. Recent studies have proved more
evidence that HRT parameters may be regarded as surro-
gate measures for baroreflex sensitivity in clinical and
prognostic evaluation in patients with CHF [13,18]. In this
study, we evaluated the clinical significance of HRT pa-
rameters in predicting prognosis in patients with CHF and
determine whether HRT parameters could be considered
as markers of the development and progression of CHF.
Methods
Ethics statement
The Ethics Committee of the First Affiliated Hospital of
Harbin Medical University approved the study design.
All patients gave informed consent in written to undergo
diagnostic and therapeutic procedure at the time of
hospitalization.
Study design and subjects
The study was performed in patients diagnosed of CHF
when admitted to the First Affiliated Hospital of Harbin
Medical University from June 2011 to December 2012.
Patients enrolled in this study must satisfy all of the fol-
lowing criteria: (1) all patients in the study had to meet
the diagnostic criteria for CHF as specified by the 1995World Health Organization/International Society and
Federation Cardiology (WHO/ISFC); [19] (2) there must
exist evidence for CHF, such as dyspnea, left/right heart
failure, cardiac dilatation and left ventricular ejection frac-
tion (LVEF) < 50%; (3) each patient presented with sinus
rhythm also had > 5 ventricular premature beats (VPBs)
measured; (4) patients diagnosed with CHF were graded
II ~ IV according to the NYHA classification [20]. Patients
were excluded based on the following criteria: (1) patients
had chronic or persistent atrial fibrillation, an implanted
permanent pacemaker or cardiac resynchronization ther-
apy; (2) patients were in the acute phase of congestive
heart failure or MI; (4) inability to perform a HRT de-
termination or reliable data analysis; (5) patients had
hypertrophic cardiomyopathy, myocarditis, diabetes, heart
disease, pulmonary heart disease or history of myocardial
infarction within 2 months; (6) patients had liver, kidney
and other serious organs diseases; (7) patients took antiar-
rhythmia drugs other than β-blocker; (8) there existed too
much interference in dynamic ECG.
In our present study, 104 CHF patients (72 males and
32 females) were enrolled with a mean age of 61.0 ±
10.0 years (range, 39 ~ 84 years). According to the NYHA
classification, these patients were divided into grade II (16
males and 7 females), grade III (20 males and 27 females)
and grade IV (27 males and 7 females) groups. There were
37 patients (28 males and 9 females) with ischemic heart
disease and 67 patients (35 males and 32 females) with
nonischemic heart disease. In addition, 30 healthy controls
(21 males and 9 females) with a mean age of 58.0 ±
9.0 years (range, 40 ~ 83 years) were enrolled in the con-
trol group after detailed medical examination, which in-
cludes medical history taking, physical examination,
chest X-ray, echocardiography, Holter monitoring and
blood biochemical examination.
Holter recording and evaluation of HRT parameters
All patients were managed under a uniform and stand-
ard assay method. HRT of CHF patients were quantified
by TO and TS acquired through the 24-hour 3-lead
Holter digital recordings (Syneflash recorder; ELA Med-
ical, Le Plessis Robinson, France) according to a pre-
viously published method [13]. HRT was analyzed using
the HRT Version 0.6 ~ 0.1 software program (Munich
Germany). TO is the difference between the mean of the
first two RR intervals after a VPB and the last two RR in-
tervals before the VPB. Positive values for TO indicate
deceleration, whereas negative values indicate acceler-
ation of the sinus rhythm. TS, the maximum positive
value of the slope of a regression line assessed over any
sequence of five subsequent sinus-rhythm RR intervals
within the first 20 sinus rhythm intervals after a VPB, are
expressed in millisecond per interval RR (ms/RR). TO >
or = 0%, TS < or = 2.5 ms/RR were considered abnormal
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study were stratified into three groups: HRT0 group with
TO < 0 and TS > 2.5 ms/normal-to-normal interval (both
factors normal); HRT1 group with either TO ≥ 0 or TS =
2.5 ms/RR (1 factor abnormal); HRT2 group with TO ≥ 0
and TS ≤ 2.5 ms/RR (both factors abnormal) [18]. For the
entire study population, time-domain measurements of
heart rate variability (HRV), including mean N-N inter-
vals, standard deviation of N-N intervals (SDNN), and
resting heart rate (RHR), left ventricular end-diastolic
dimension (LVEDD) were calculated from the 24-hour
Holter ECG recording. The RHR was measured after
5 minutes rest while seated in a quiet room [21].
Two-dimensional and Doppler echocardiographic ex-
aminations were performed with a HP5500 ultrasound
system (Hewlett Packard, Andover, Mass, USA). In the
parasternal long-axis view, M-mode echocardiograms
were made of left ventricle from the left hemithorax in
short-axis.Follow-up
The median duration of the entire study follow-up was
10.5 ± 8.3 months (range, 6 ~ 18 months). All events re-
corded in the study were adjudicated blindly by an ad-
hoc committee on the basis of pre-agreed definitions
and procedures. Follow-up information was collected for
all patients through outpatient service and phone calls.
The end point was prospectively defined as the compo-
site of heart failure and cardiac mortality.
The assessment follow-up period lasted until January
31, 2013. Finally, the overall mortality of CHF patients
was 9.6% (10/104). There were 32 CHF patients (26
males and 6 females) exhibiting a deterioration of car-
diac function and 62 patients showing no significant






CHF patients Grade II (n = 23) 6 13 5
Grade III (n = 47) 8 23 16
Grade IV (n = 34) 1 10 22
Healthy controls (n = 30) 22 7 1
HRT, heart rate turbulence; CHF, chronic heart failure; NYHA, the New York
Heart Association.Statistical analysis
Data were expressed as mean ± standard deviation (mean ±
SD) unless otherwise specified and qualitative data are pre-
sented as percentages. Comparative analyses between
the groups were performed with the Student’s t-test for
continuous variables and χ2 or Fisher’s exact test for
dichotomous parameters. Correlation between auto-
nomic markers was assessed with Spearman correl-
ation coefficient. Survival curves were estimated with
the Kaplan-Meier method and compared by the log-
rank test. Independent predictors of death were identified
with multivariate Cox proportional hazards model and
expressed as hazard ratio (HR) with 95% confidence inter-
val (CI). A P value of less than 0.10 was considered statis-
tically significant and all tests were two-sided. All analyses
were performed using the SPSS 18.0 software (SPSS, Inc.,
Chicago, IL, USA).Results
Comparison of heart rate turbulence
The differences in HRT between CHF patients and
healthy subjects are summarized in Table 1. Our results
revealed that CHF patients exhibited a significant re-
duction in HRT levels. CHF patients had higher levels
of TO than those of healthy subjects (0.48 ± 1.58%
vs. -1.73 ± 2.58%, P < 0.001), but the TS levels of CHF pa-
tients were lower than that of the control group (1.88 ±
1.99 vs. 4.41 ± 1.71 ms/RR, P < 0.001). There was a signifi-
cant difference in the rate of HRT1/2 between CHF pa-
tients and healthy controls (89/104 vs. 22/30, P < 0.001).
Furthermore, CHF patients with NYHA grade IV had
higher HRT1/2 rate than those with NYHA grade II/III
(P = 0.013, 0.051, respectively) (Figure 1).
Relevance factors of HRT
Correlation analyses indicated that TO negatively cor-
related with SDNN (r = −0.316, P < 0.001), but no asso-
ciations were found between TO and other factors (all
P > 0.05). TS positively correlated with SDNN (r =
0.270, P < 0.001) and LVEF (r = 0.365, P < 0.001). How-
ever, there were negative associations between TS and
LVEDD (r = −0.313, P < 0.001), RHR (r = −0.299, P =
0.001), Hcy (r = −0.198, P < 0.001) and CRP (r = −0.278,
P < 0.001). We also observed no correlations with TS to age
and TC levels (both P > 0.05). Correlations of TO and TS
with relevance factors are shown in Table 2 and Figure 2.
Comparison of CHF patients with different prognosis
Our results suggested that there were statistical differ-
ences in TS, LVEF, SDNN and RHR between the non-
deteriorating group and the non-survivor group (all P <
0.05, as shown in Table 3). We observed a significant
difference in TS among the three groups (all P < 0.05).
Furthermore, CHF patients in the non-survivor group had
lower levels of TS than those in the deteriorating group
(P < 0.001).
Survival analysis
Univariate survival analysis demonstrated that age (≥65),
LVEF (≤30%), SDNN (≤100 ms), RHR (≥75 bpm), HRT1











Figure 1 Difference in HRT levels between CHF patients with different NYHA grade and healthy controls.
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patients (all P < 0.05) (Table 4). Multivariate Cox regres-
sion analysis indicated that LVEF (≤30%), HRT2, SDNN
and RHR were independent risk factors for poor progno-
sis in CHF patients (all P < 0.05) (Table 5). Among these
risk factors, HRT2 was the strongest predictor of CHF
with a high hazard risk of 5.12. The survival curve also
showed that the survival rate of CHF patients with
HRT0 and HRT1 were higher than those with HRT2 (all
P < 0.05) (Figure 3).
Discussion
HRT is a baroreflex-mediated biphasic reaction of heart
rate in response to premature ventricular beats [22].
Generally, abnormal HRT is widely accepted to be indica-
tive of potential autonomic dysfunction or impaired barore-
flex sensitivity in patients due to variety of disorders; it may
also reflect changes in autonomic nervous system induced
by different therapeutic modalities such as drugs, revas-
cularization, or cardiac resynchronization therapy [15,23].
More importantly, impaired HRT has been demonstratedTable 2 Correlations of TO and TS with relevance factors
Factors TO TS
r P r P
Age 0.760 0.401 −0.600 0.505
LVEDD 0.152 0.090 −0.313 <0.001
LVEF −0.268 0.060 0.365 0.001
SDNN −0.316 <0.001 0.270 0.020
RHR 0.211 0.180 −0.299 0.010
TC 0.359 0.301 −0.640 0.305
Hcy 0.314 0.062 −0.198 <0.001
CRP 0.218 0.052 −0.278 <0.001
TO, turbulence onset; TS, turbulence slope; LVED, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; SDNN, standard deviation of
N-N intervals; RHR, resting heart rate; TC, total cholesterol; Hcy, homocysteine;
CRP, C-reaction protein.in identifying patients at high risk for all-cause mortality
and sudden death, particularly in post-infarction and con-
gestive heart failure patients [24]. Notably, HRT have a
higher specificity and sensitivity as compared to some
other detection methods since it is a bi-physiological re-
sponse of the interaction between sinus and ventricular
contraction that reflect the sensitive outcome of extremely
weak endogenous stimuli triggering reflex regulation
[25,26]. In recent decades, increasing number of clinical
applications in HRT have gained global popularity as
well as considerable successes, and it has been previ-
ously described as an independent predictor of mortality
in patients with cardiovascular diseases [27,28].
Generally, HRT is described as the acceleration and
subsequent deceleration of sinus rate [29]. Abnormal
HRT has a well-established role in the stratification of
post-infarction and heart failure in patients [30]. How-
ever, current emphasis on the medical application of
HRT is far from perfect, and its function has not been
fully assessed. In this study, we evaluated the relation-
ships between HRT parameters and prognosis in CHF
patients to explore the predictive values of HRT parame-
ters in the development and progression of CHF. This
study revealed that CHF patients exhibited a significant
reduction in HRT levels with higher TO levels and lower
TS levels than the healthy subjects, suggesting that the
HRT levels may be closely related to the development
and progression of CHF. Although the exact reasons for
HRT reduction in patients with CHF are not fully under-
stood, a potential explanation could be that CHF pa-
tients may suffer from myocardial deformation or
damages in the terminal receptors, and abnormal sym-
pathetic and vagal afferent stimulation, which may lead
to dullness of baroreflex, cause decreased HRT or dis-
appearance of HRT after VPBs in patients with organic
heart disease [31]. Sredniawa et al. demonstrated that
CHF patients were associated with more abnormal average


























































Figure 2 Correlations of HRT parameters (TO and TS) with SDNN, RHR and LVEDD.
Table 3 Comparison of CHF patients with different
prognosis
Factors Non-deteriorating
group (n = 62)
Deteriorating
group (n = 32)
Non-survivor
group (n = 10)
Age 64.78 ± 11.92 60.63 ± 10.25 60.12 ± 10.34
TO 0.33 ± 1.64 0.23 ± 1.53 0.95 ± 1.63
TS 2.50 ± 2.61 2.15 ± 1.82※ 0.87 ± 1.33※#
LVEDD 44.58 ± 10.12 41.24 ± 7.24 26.82 ± 8.86※
LVEF 56.15 ± 7.17 53.31 ± 9.01 61.01 ± 9.40
SDNN 102.88 ± 36.98 97.28 ± 34.88 95.57 ± 31.66※
RHR 76.65 ± 15.23 83.48 ± 12.76 89.58 ± 14.07※
TC 4.56 ± 4.36 4.16 ± 0.16 3.16 ± 0.62
Hcy 8.59 ± 2.06 14.55 ± 4.11 16.95 ± 6.30
CRP 7.71 ± 1.22 11.84 ± 2.96 12.67 ± 5.67
CHF, chronic heart failure; TO, turbulence onset; TS, turbulence onset; LVEDD,
left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction;
SDNN, standard deviation of N-N intervals; RHR, resting heart rate; TC, total
cholesterol; Hcy, homocysteine; CRP, C-reaction protein; ※P < 0.05 compared
with the non-deteriorating group; #P < 0.05 compared with the
non-deteriorating group.
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progression toward end-stage heart failure or all-cause
mortality of CHF patients [18]. Analysis of HRT is an easy
and innocuous way to assess the parasympathetic nervous
system, and it can be used as a prognostic marker both in
ischemic heart disease and heart failure; in some cases, it
even has a better correlation than LVEF [32]. We also
found a significant difference in HRT1/2 rate between CHFTable 4 Univariate survival analysis of HRT parameters
with prognosis of CHF patients
HR (95% CI) P value
Age 3.91 (1.03, 19.56) 0.048
HRT0 1.34 (0.50, 3.38) 0.648
HRT1 3.78 (1.86, 7.01) 0.010
HRT2 5.40 (2.65, 25.48) 0.015
LVEF 4.96 (1.83, 17.20) 0.020
LVEDD 2.70 (1.08, 7.36) 0.038
SDNN 3.95 (1.11, 14.02) 0.034
RHR 4.04 (1.39, 20.95) 0.015
HRT, heart rate turbulence; CHF, chronic heart failure; HR, hazard risk; LVEF, left
ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter;
SDNN, standard deviation of N-N intervals; RHR, resting heart rate.
Table 5 Multivariate cox regression analysis of HRT
parameters with prognosis of CHF patients
HR (95% CI) P value
HRT1 5.12 (1.53, 16.37) 0.022
HRT2 4.68 (1.54, 16.78) 0.030
LVEF 1.37 (0.84, 2.13) 0.123
LVEDD 3.69 (1.32, 11.46) 0.046
SDNN 3.18 (1.69, 17.43) 0.034
RHR 1.84 (0.77, 2.46) 0.152
HRT, heart rate turbulence; CHF, chronic heart failure; HR, hazard risk; LVEF,
left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter;
SDNN, standard deviation of N-N intervals; RHR, resting heart rate.
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with NYHA grade IV had a higher positive rate of HRT1/2
than those with NYHA grade II/III, revealing that HRT was
correlated with the severity of CHF. The observation of
more depressed HRT in patients with advanced NYHA
functional class is also consistent with previous reports and
studies [33]. In addition, our study also found statistical dif-
ferences in TS, LVEF, SDNN and RHR between the non-
deteriorating group and the non-survivor group; significant
differences in TS among the three groups were also ob-
served. Moreover, correlation analyses indicated that both
the TS and TO were significantly correlated with SDNN
and that only TS was significantly correlated with LVEF.
These findings revealed that TS could be considered as a
stronger predictor of hospitalization for worsening heart
failure and death in CHF patients than LVEF, SDNN and
RHR. The mechanisms of the decreased TS in CHF pa-
tients are not clear; it is likely that the TS is moreSurvival Cu
Survival t


















Figure 3 Survival curve for the survival rate of CHF patients with HRTsusceptible to CHF events because it correlates with both
the left ventricular function and the cardiac autonomic
status [34]. Consistent with our results, a previous study
suggested that the TS appears to be a more suitable prog-
nostic marker for CHF death and hospitalization than
LVEF and SDNN, which further confirmed that HRT
serves great predictive value in the prognosis of CHF [35].
Univariate survival analysis demonstrated that age (≥65),
LVEF (≤30%), SDNN (≤100 ms), RHR (≥75 bpm), HRT1
and HRT2 were associated with poor prognosis of CHF
patients. Multivariate Cox regression analysis indicated
that LVEF (≤30%), HRT2, SDNN and RHR were independ-
ent risk factors for poor prognosis of CHF patients.
Among these risk factors, HRT2 (the combination of ab-
normal TO and TS) was the strongest predictor of CHF
with a high hazard risk of 5.12 after CHF and remained
highly significant after adjustment for LVEF and other
clinical risk factors. The combination of abnormal TO
and TS may result in tachycardia which would cause de-
creased heart efficiency in increased myocardial oxygen
consumption, decreased myocardial perfusion during
myocardial relaxation and diastolic, thereby leading to
myocardial injury and aggravating or worsening heart
failure [36]. Nevertheless, some limitations of this study
should be acknowledged. Firstly, a lack of image analysis
software to automatically identify and analyze the matched
VPBs, as well as HRT, limited the accuracy in the prog-
nostic significance of HRT in CHF patients. Secondly,
HRT level is easily affected by various factors, therefore
certain limitations still remain in the sensitivity, specificity
and positive predictive value of HRT in CHF patients.rve
ime (months)




0, HRT1 and HRT2.
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small sample size, the correlation between HRT and CHF
requires further verification.
Conclusions
Our findings indicated that HRT may have good clinical
predictive values in patients with CHF. Thus, quantifying
HRT parameters could be useful tool in predicting mor-
tality in CHF patients. However, due to the limitations
mentioned above, further detailed studies with larger
sample size and longer follow-up periods are still re-
quired to confirm our results.
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